Drug Profile


Alternative Names: RDEA-594; RDEA594 sodium; Zurampic

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Ardea Biosciences
  • Developer Ardea Biosciences; Ironwood Pharmaceuticals
  • Class Acetic acids; Antigouts; Cyclopropanes; Naphthalenes; Small molecules; Sulfides; Triazoles; Uricosurics
  • Mechanism of Action SLC22A12 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gout

Most Recent Events

  • 22 Feb 2017 Ironwood Pharmaceuticals has patent protection for lesinurad in USA (Ironwood Pharmaceuticals 10-K, February 2017)
  • 22 Feb 2017 Ironwood Pharmaceuticals has patents pending for lesinurad in USA (Ironwood Pharmaceuticals 10-K, February 2017)
  • 11 Nov 2016 Pooled efficcy and adverse events data from phase III Long-term extension studies for the CLEAR and CRYSTAL trials in Gout presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR-ARHP-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top